Your session is about to expire
← Back to Search
Cell-based Immunotherapy
Leukapheresis for Coronavirus
N/A
Waitlist Available
Research Sponsored by Serhat Gumrukcu, MD PhD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 100 days
Awards & highlights
Study Summary
Changes in Cellular Immune Profile During COVID-19 Infection
Eligible Conditions
- Coronavirus
- COVID-19
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 100 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 100 days
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Cellular immune system profiling
Secondary outcome measures
Expansion of virus-specific innate immune cells
Innate immune system profiling
Side effects data
From 2017 Phase 2 trial • 20 Patients • NCT0109705710%
Hyperglycemia
5%
DVT
5%
Febrile Neutropenia
5%
Cellulitis
5%
Atrial Fibrillation
100%
80%
60%
40%
20%
0%
Study treatment Arm
Treatment (Rituximab, Etoposide, Carboplatin, Ifosfamide)
Trial Design
1Treatment groups
Experimental Treatment
Group I: Single armExperimental Treatment1 Intervention
Venous blood and apheresis collection will be conducted
Find a Location
Who is running the clinical trial?
Serhat Gumrukcu, MD PhDLead Sponsor
1 Previous Clinical Trials
12 Total Patients Enrolled
The Scripps Research InstituteOTHER
30 Previous Clinical Trials
10,557 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger